Patent · US Active

Method of treatment using organotypically cultured skin tissue comprising niks cells that express exogenous HIF-1a

US7988959B2 · kind B2 · utility

4Cited by
14References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 21, 2010
Grant dateAug 2, 2011
Priority date
Expiry dateSep 21, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2502/99
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1α, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.